

Oncology Today with Dr Neil Love: NSCLC with EGFR Exon 20 Insertion Mutations

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Which of the following values best represents the frequency of EGFR sensitizing mutations in non-small cell lung cancer (NSCLC)?
 - ~2%
 - ~12%
 - ~20%
 - ~33%
- Which of the following statements best describes the role of EGFR tyrosine kinase inhibitors (TKIs) for patients with EGFR exon 20 insertions?
 - EGFR TKIs are generally not active in these patients
 - The efficacy of EGFR TKIs is superior to that of immunotherapy
 - The efficacy of EGFR TKIs is superior to that of platinum-based chemotherapy
- Which of the following ranges best represents the partial response rate with mobocertinib for patients with EGFR exon 20 insertions in the PPP (platinum-pretreated) and "EXCLAIM" cohorts?
 - 0% to 10%
 - 10% to 20%
 - 20% to 30%
 - 30% to 40%
- A median overall survival of 22.8 months was reported which of the following agents for patients with NSCLC and EGFR exon 20 insertions?
 - Mobocertinib
 - Amivantamab
 - Pozitotinib
 - None of the above